Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

MULTIFUN · Multifunctional Nanotechnology for selective detection and Treatment of cancer

FP7Status: CLOSED13 June 201112 June 2015EU funding €9,799,994

The aim of the MultiFun consortium is to develop and validate a novel and minimally-invasive nanotechnology system to improve cancer diagnosis and treatment. MultiFun nanotechnology is based on multifunctionalised magnetic nanoparticles to selectively target and eliminate breast and pancreatic cancer (stem) cells. The improved magnetic features of the MultiFun magnetic nanoparticles will lead to potential medical applications such as contrast agents and magnetic heating inductors. Moreover, magnetic nanoparticles can be functionalised with ligands to increase their affinity towards cancer cells in order to facilitate diagnosis of tumours by MRI. Targeting peptides and antibodies will be employed, including antibodies against cancer stem cells leading to early cancer detection by MRI means. The same nanoparticles will be used simultaneously as functional nanocarriers and heating inductors in order to provide a combined therapeutic modality. The synergistic effects of drugs, peptides, small RNAs and heat will be evaluated to determine the effectiveness of different therapeutic combinations. Interestingly, the use of ligands will favour the specific application of the therapeutic modalities to cancer (stem) cells, increasing the effectiveness and reducing side effects. Thus, MultiFun multimodal therapeutic approach is designed to efficiently remove cancer cells, including cancer stem cells, from the tumour site. The toxicity of functionalised magnetic nanoparticles will be assessed in vitro and in vivo to warrant a safe use and shed some light on the risks. The distribution and activity evaluation of functionalised nanoparticles will be performed in human breast and pancreatic cancer xenograft models. The use of novel magnetic nanoparticles for biomedical applications provides opportunities for new instrumentation: 1) detection and quantification of magnetic nanoparticles in blood, urine and tissues, and 2) magnetic heating induction for raising cell temperature.

Consortium · 17 organisations

coordinator

ATOS SPAIN SA

ES · €810,390

participant

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

ES · €445,920

participant

THE UNIVERSITY OF MANCHESTER

UK · €838,107

participant

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN

IE · €1,059,807

participant

INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE TOULOUSE

FR · €518,020

participant

FYZIKALNI USTAV AV CR V.V.I

CZ · €449,999

participant

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS

ES · €1,213,573

participant

PHARMA MAR SA

ES · €219,912

participant

SOLUCIONES NANOTCNOLOGICAS SL

ES

participant

UNIVERSITE PARIS XII VAL DE MARNE

FR · €321,050

participant

PEPRIC NV

BE · €496,148

participant

LIQUIDS RESEARCH LTD

UK · €402,823

participant

FUNDACION IMDEA NANOCIENCIA

ES · €875,680

participant

QUEEN MARY UNIVERSITY OF LONDON

UK · €274,496

participant

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

IE · €298,972

participant

KING'S COLLEGE LONDON

UK · €571,937

participant

UNIVERSITATSKLINIKUM JENA

DE · €1,003,160

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.